Wednesday, October 14, 2026

Inter & Co's 65.6% CDI Funding Cost Sets Brazilian Banking Benchmark as AI Risk Models Separate Digital from Traditional Lenders

Inter & Co achieved 65.6% CDI funding costs—the lowest among major Brazilian financial institutions—while maintaining risk-adjusted margins through AI-powered credit assessment. Nu Holdings deployed its nuFormer AI model in production during 2025, keeping risk-adjusted net interest margins stable despite regulatory headwinds affecting government-backed lending programs. Digital banks with machine learning credit models are now establishing measurable cost advantages over traditional competitors.

Inter & Co's 65.6% CDI Funding Cost Sets Brazilian Banking Benchmark as AI Risk Models Separate Digital from Traditional Lenders
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Inter & Co recorded 65.6% CDI (Certificado de Depósito Interbancário) funding costs in Q4 2024, the lowest rate among Brazilian financial institutions serving over 20 million clients. The metric reflects borrowing costs as a percentage of Brazil's benchmark interbank rate.

Nu Holdings kept risk-adjusted net interest margins flat quarter-over-quarter after removing the impact of FGTS (Fundo de Garantia do Tempo de Serviço) program changes, according to CFO Guilherme Lago. The government program adjustment reduced margins industry-wide, but Nu's AI systems maintained underlying credit performance.

Both banks deployed production AI credit models during 2025. Nu's nuFormer system processes loan applications using machine learning trained on over 100 million customer data points. Inter's newer client cohorts transact faster and more frequently than earlier users, indicating improved targeting from algorithmic underwriting.

Traditional Brazilian banks operate with funding costs 15-20 percentage points higher than Inter's rate. The gap stems from digital banks' data-driven customer selection and automated risk pricing, which reduce default rates and allow lower interest offers to depositors.

Inter became Brazil's fastest-growing financial institution among those exceeding 20 million clients. Growth correlates with the bank's ability to price loans more precisely than competitors lacking real-time risk models.

The funding cost advantage creates a compounding effect: lower deposit rates improve margins, which funds customer acquisition, which generates more training data for AI models. Digital banks with this flywheel can underprice traditional lenders while maintaining profitability.

Brazil's Central Bank requires all banks to maintain minimum capital ratios regardless of loan performance technology. AI models help digital banks optimize within these constraints by identifying lower-risk borrowers who would receive identical treatment under traditional underwriting.

The 2026-2027 period will test whether AI credit advantages persist through economic cycles. Brazilian interest rates remain volatile, and machine learning models trained during growth periods may underperform in downturns. Non-performing loan rates across both digital and traditional banks will determine if current efficiency gaps reflect permanent structural advantages or temporary market conditions.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com